Significant’ weight returned weeks after stopping drug, say researchers who advise patients to adjust expectations.

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Men receiving tirzepatide showed greater reductions in body weight and waist circumference and improvements in erectile ...

The President’s CVI diagnosis underscores the need for earlier recognition — and more acceptable treatments — for a ...

Scientists found that obesity may exist in 11 biological forms, each linked to different genes and body functions.

The MC4R agonist targets rare genetic and hypothalamic obesity, with potential as a combination or maintenance therapy for general obesity alongside GLP-1 agents.

Clinical trial data review on weight-loss drugs reveals weight regain patterns post-medication discontinuation, impacting weight management strategies.

The prevalence of long COVID-typical symptom clusters was relatively high among a cohort of adults 2 years after initial COVID-19 infection.

A key weight-loss drug goes off-patent next year. A US study estimates its production cost to be less than 2% of its selling ...

Explore how semaglutide and tirzepatide may protect against dementia and stroke—keep reading for clinical implications and evidence.

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the ...